Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated Patients with Mantle Cell Lymphoma By Ogkologos - October 24, 2025 163 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENRICH study Source RELATED ARTICLESMORE FROM AUTHOR New Survey Highlights the Role of Clinical Practice Guidelines to Improve Care for Patients with Rare Cancers FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF V600E Mutation In Memory of Hernán Cortés-Funes: Former ESMO President and Pioneer in Medical Oncology MOST POPULAR Why Have Thyroid Cancer Diagnoses Spiked for US Women? September 28, 2021 Expressive Writing, What is It? May 12, 2021 74 & 75-Year-Old Sweethearts Get Married In ICU In Wake Of... February 10, 2022 Mom Wants Disney To Ban Childless Adults From Their Theme Parks July 29, 2019 Load more HOT NEWS How erectile dysfunction drugs could be the key to overcoming treatment... Dual Antigen Targeting with Talquetamab plus Teclistamab in Patients with Relapsed... On your marks, get set… start-up! Nivolumab Does Not Prolong Overall Survival Compared with Sorafenib In First-Line...
